Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-7254
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson’s disease ; day:27 ; month:7 ; year:2022 ; pages:1-12
Acta pharmacologica Sinica ; (27.7.2022), 1-12
- Creator
-
Dong, An-qi
Yang, Ya-ping
Jiang, Shu-min
Yao, Xiao-yu
Qi, Di
Mao, Cheng-jie
Cheng, Xiao-yu
Wang, Fen
Hu, Li-fang
Liu, Chun-feng
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41401-022-00951-1
- URN
-
urn:nbn:de:101:1-2022100820582644971634
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dong, An-qi
- Yang, Ya-ping
- Jiang, Shu-min
- Yao, Xiao-yu
- Qi, Di
- Mao, Cheng-jie
- Cheng, Xiao-yu
- Wang, Fen
- Hu, Li-fang
- Liu, Chun-feng
- SpringerLink (Online service)
Other Objects (12)
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis
Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of β-arrestin2 and NLRP3
TREM2 Deficiency Aggravates NLRP3 Inflammasome Activation and Pyroptosis in MPTP-Induced Parkinson’s Disease Mice and LPS-Induced BV2 Cells
The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson’s disease via the microglial NLRP3 inflammasome
lincRNA-Cox2 regulates NLRP3 inflammasome and autophagy mediated neuroinflammation
Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients
Dysregulation of autophagy and mitochondrial function in Parkinson’s disease
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis
Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of β-arrestin2 and NLRP3
TREM2 Deficiency Aggravates NLRP3 Inflammasome Activation and Pyroptosis in MPTP-Induced Parkinson’s Disease Mice and LPS-Induced BV2 Cells
The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson’s disease via the microglial NLRP3 inflammasome
lincRNA-Cox2 regulates NLRP3 inflammasome and autophagy mediated neuroinflammation
Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients
Dysregulation of autophagy and mitochondrial function in Parkinson’s disease
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis
Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of β-arrestin2 and NLRP3
TREM2 Deficiency Aggravates NLRP3 Inflammasome Activation and Pyroptosis in MPTP-Induced Parkinson’s Disease Mice and LPS-Induced BV2 Cells
The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson’s disease via the microglial NLRP3 inflammasome
lincRNA-Cox2 regulates NLRP3 inflammasome and autophagy mediated neuroinflammation
Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients
Dysregulation of autophagy and mitochondrial function in Parkinson’s disease